NEW YORK (GenomeWeb News) – Protagen said today that it has entered a collaboration agreement with Pfizer to use its SeroTag technology to identify biomarkers in support of Pfizer's drug development work.

Specifically, the collaboration aims to identify markers for stratifying patient cohorts or predicting patient response to a novel autoimmune disease drug being developed by Pfizer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.